Vertex tests shorter Incivek therapy in patient subset

Vertex Pharmaceuticals ($VRTX) will put its Incivek hepatitis C treatment through a trial to determine whether combination therapy for the disease could be shortened to 12 weeks in patients with a particular genetic variation associated with a stronger and faster response to antiviral therapy. Vertex release

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.